1. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical target in Huntington’s disease. Department of Pharmacological Sciences and Centre for Stem Cell Research, Universita` degli Studi di Milano, Milan, Italy
2. Laforet GA, SappE, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Hemachandra Reddy P, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N, Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington’s Disease (2001) Departments of Psychiatry and Medicine, University of Massachusetts Medical School, Worcester, MA, Department of Neurology, Massachusetts General Hospital, Boston, MA, Genetics and Molecular Biology Branch, National Genome Research Institute, National Institutes of Health, Bethesda, MD, Mental Retardation Research Center, University of California at Los Angeles, Los Angeles, CA, and Department of Neuroscience, Chicago Medical School, North Chicago, IL, J Neurosci 21(23):9112–9123
3. Maria Damiano, Laurie Galvan,Nicole Diglon, Emmanuel Brouillet, Mitochondria in Huntington's disease, Elsevier 11 August 2009
4. Mitochondria in Huntington’s disease CEA, DSV, I2BM Molecular Imaging Research Center (MIRCen), CEA, CNRS URA 2210, F-92265 Fontenay-aux-Roses, France, 31 July 2009
5. Yamamoto A†, Lucas JJ†‡, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease, Center for Neurobiology and Behavior Columbia University New York, New York, Cell, vol. 101, pp 57–66